SOURCE: Corcept Therapeutics

Corcept Therapeutics

October 29, 2015 16:05 ET

Corcept Therapeutics to Announce Third Quarter Financial Results and Corporate Update and Host Conference Call

MENLO PARK, CA--(Marketwired - Oct 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information
To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 41022099.

A replay will be available through November 19, 2015 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 41022099.

About Corcept Therapeutics Incorporated
Corcept discovers, develops and commercializes drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company's first FDA-approved medication. The company is conducting a Phase 1/2 trial of Korlym for the treatment of triple-negative breast cancer and is planning Phase 2 studies of CORT125134, one of its next-generation selective cortisol modulators, for the treatment of Cushing's syndrome and an oncology indication. The company has developed a proprietary portfolio of other compounds that modulate the effects of cortisol, but not progesterone. It holds composition of matter patents on these molecules. Corcept also owns or has exclusively licensed extensive intellectual property covering the use of cortisol modulators, including Korlym, in the treatment of a wide variety of serious disorders.

Contact Information